Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.

Implementation

NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.

Is this guidance up to date?

In October 2018, NICE started the review of this guidance. To register as a stakeholder, please contact us at medtech@nice.org.uk.

Guidance development process

How we develop NICE medical technologies guidance

NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

Clinical coding recommendations

Coding relevant to this guidance

OPCS-4

NICE guidance states that this is for use in a community setting, this being primary care. OPCS-4 is only mandated for use in secondary care in the admitted patient care dataset. As this would be carried out by a nurse in community setting no OPCS-4 code would be assigned. Unless this is being considered for inpatients, the patients would need to be admitted under a consultant in order that and FCE to be generated OPCS-4 code assigned.

Possible OPCS-4 code if needed: wound debridement S57.1

SNOMED CT

Procedure:

939871000000108 | Debridement of wound of skin using debridement pad (procedure)

Device:

19273111000001103 | Physical debridement pad (physical object)

19257811000001102 | DebriSoft pad 10cm x 10cm (Activa Healthcare Ltd) (physical object)

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)